Ashton Tweed Connection Vol. 3 No. 6

Featuring CEO Interview with Gur Roshwalb, MD, CEO, Akari Therapeutics Plc

Volume 3, Number 6

Whether you are or you require executive or management talent — interim, permanent, or interim to hire — Ashton Tweed can meet your specialized retained search and executive search needs.

CEO Leadership Series: Gur Roshwalb, MD, CEO, Akari Therapeutics Plc

Gur Roshwalb, M.D., isn’t afraid of a challenge. When Dr. Roshwalb, CEO of Akari Therapeutics Plc, saw a unique opportunity to reinvent a well funded but struggling U.S. biotech company by merging it with a cash-strapped British company with a promising new drug therapy for patients with rare conditions, he took it.

Strategic Partnerships For Small Life Science Companies

It’s very common for life sciences companies to enter into strategic partnerships, whether they’re small start-ups or large established businesses, because it’s an effective way to share expertise, resources, and funds. As a small company or start-up, especially if you are in the research and development phase, you require funding to survive. This can come in the form of investors and partnerships…

The Right Way to Reach Out to Recruiters During Job Search

Recruiters can be used as a valuable tool during your job search because they are in the business of people and therefore are great connections to add to your network. Although each firm is different, many are receptive to speaking with job searching candidates, but there are right and wrong ways to introduce yourself to recruiters. Make sure to follow the guidelines below in order to reach out to…


	YOUR TOP LIFE SCIENCES HIRING NEWS! SUBSCRIBE TODAY FOR ASHTON TWEED’S WEEKLY DIGEST EMAILS THAT COVER HIRING, FIRING, AND RETIRING NEWS IN THE LIFE SCIENCES INDUSTRY:

Google teams up with GSK to develop ‘bioelectronic medicines’

Verily, formerly Google Life Sciences, teams up with GlaxoSmithKline to develop bioelectronic medicines that can “harness electrical signals in the body to treat chronic disease.” Both companies will invest up to $715 million to form Galvani Bioelectronics…

Ice Bucket Challenge Helped Lead to New ALS Gene Discovery

Ice Bucket Challenge Helped Lead to ALS Gene Discovery

An international research team funded by The ALS Association’s ALS Ice Bucket Challenge donations has identified a new ALS gene. The gene, NEK1, now ranks among the most common genes that contribute to the disease. Their study provides another potential target for therapy…

Gene-Therapy Cure Has Money-Back Guarantee

Strimvelis is the first gene-therapy cure for a rare disorder. Its recently announced cost of $665,000 makes it one of the most expensive one-time treatments ever sold. However, if it doesn’t work, the money will be returned. Strimvelis uses a virus to add a missing gene to the bone marrow of children with ADA-SCID, an inability to fight…

CRISPR patent battle heats up as new email disputes Zhang's claim

CRISPR patent battle heats up as new email disputes Zhang claim

The ongoing patent battle over who owns the rights to the CRISPR-Cas9 technology has heated up with a new email. Biochemist Dr. Jennifer Doudna, from the University of California, Berkeley, and biologist Feng Zhang, from the Broad Institute of Harvard and MIT, both claim to have invented the tech…

Merck enters race for cancer drugmaker Medivation

Merck & Co. Inc. has shown interest in buying Medivation Inc. earlier this month. Medivation, best known for its prostate cancer drug Xtandi, has already rejected two acquisition offers from Sanofi. Pfizer Inc., Celgene Corp., and Gilead Sciences Inc. have also shown interest. Sources asked not…

When measuring success in pharma, one highly monitored measurement is the amount of revenue a company generates from new medicines. But is it a reliable measure of success? A Bloomberg Intelligence analysis of drugs approved since 2010 shows Bristol-Mye…

Read the Label on Pharma's New Drug Sales

Electronics developer and interconnected solutions company Molex is buying Phillips-Medisize for an undisclosed amount, with an expected closing date in the fall. Molex and Phillips-Medisize’s combined skills will help them become a global leader in connected health…